A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

NCT ID: NCT07225140

Last Updated: 2025-11-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-28
• Study Completion Date: 2026-10-31

Brief Summary

Combogesic® 325 contains a combination of ibuprofen and acetaminophen. The purpose of this study is to compare the pain relief effects of Combogesic® 325mg and acetaminophen and to evaluate the safety of Combogesic® 325mg in adolescents between the ages of 12 and <18 years.

What will the study involve for participants?

• Participants will be randomly allocated to one of 3 treatment groups:

• 3 tablets of Combogesic® 325,
• 2 tablets of Combogesic® 325 and 1 tablet of placebo or
• 2 tablets of acetaminophen1000mg and 1 tablet of placebo
• Participants will take 3 tablets every 6 hours with a maximum of 4 doses in 24 hours
• Participants and study doctor will be blinded to the treatment group
• If pain is not sufficiently controlled, opioids may be used as supplementary pain relief at the discretion of the study doctor.
• Participants will complete a patient diary to assess their pain
• Participants will rate the study drug at the end of the treatment.

It is expected that Combogesic® tablets (either 2 or 3 tablets per dose) will provide a greater reduction in pain compared to acetaminophen (1000 mg) treatment.

Conditions

Post Operative Pain, Acute

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment A- 3 tablets of Combogesic® tablets

3 tablets of Combogesic® (acetaminophen 975mg + ibuprofen 292.5 mg, total per dose) will be administered every 6 hours up to a maximum of 4 doses in 24 hours.

Group Type: EXPERIMENTAL

Combogesic® tablets

Intervention Type: DRUG

The active ingredients of Combogesic® tablets are acetaminophen 325 mg and ibuprofen 97.5 mg.

Treatment B- 2 tablets of Combogesic® + 1 tablets of placebo

2 tablets of Combogesic® (acetaminophen 650 mg + ibuprofen 195 mg, total per dose) and 1 tablet of placebo will be administered every 6 hours up to a maximum of 4 doses in 24 hours.

Group Type: EXPERIMENTAL

Combogesic® tablets

Intervention Type: DRUG

The active ingredients of Combogesic® tablets are acetaminophen 325 mg and ibuprofen 97.5 mg.

Placebo

Intervention Type: DRUG

Placebo tablets do not contain any active ingredients

Treatment C - 2 tablets of acetaminophen and 1 tablet of placebo

2 tablets of acetaminophen (1000 mg total per dose) + 1 tablet of placebo will be administered every 6 hours up to a maximum of 4 doses in 24 hours.

Group Type: ACTIVE_COMPARATOR

Acetaminophen 500mg

Intervention Type: DRUG

Each tablet contains acetaminophen 500mg.

Placebo

Intervention Type: DRUG

Placebo tablets do not contain any active ingredients

Interventions

Combogesic® tablets

The active ingredients of Combogesic® tablets are acetaminophen 325 mg and ibuprofen 97.5 mg.

Intervention Type: DRUG

Acetaminophen 500mg

Each tablet contains acetaminophen 500mg.

Intervention Type: DRUG

Placebo

Placebo tablets do not contain any active ingredients

Intervention Type: DRUG

Other Intervention Names

Acetaminophen 325 mg and ibuprofen 97.5 mg

Eligibility Criteria

Inclusion Criteria

• Provide written informed consent or consent be provided from parents/legal guardians and assent from participants (where appropriate).
• Be males and females aged at least 12 years and less than 18 years old on both the day of consent and throughout the 24 hour study period.
• Be undergoing planned orthopedic surgery which requires at least 24 hours of hospital inpatient stay.
• Have a clinical indication of acute moderate or severe pain (at least ≥ 50 mm on the VAS scale*) within 6 hours after the completion of surgery associated with orthopedic surgery.
• using a 100mm VAS scale with 0 = no pain and 100 = worst pain imaginable, patients should have a resting VAS pain intensity score of ≥ 50 mm for inclusion. For this study, moderate pain is defined as ≥ 40 mm to ≤ 69 mm and severe pain is defined as a resting VAS of ≥ 70 mm to ≤ 100 mm.
• Have negative HIV and hepatitis B & C test results.

Exclusion Criteria

• Has taken any NSAID or acetaminophen containing drug products within 5 half-lives prior to the initial dose of study drug.
• Hypersensitivity to opioids, NSAIDs or acetaminophen or a history of severe/serious drug reaction to NSAIDs or acetaminophen.
• Pregnant or lactating females Known to be pregnant or possibly pregnant.
• Sexually active females of childbearing potential not using adequate contraception* and sexually active males not using adequate contraception**
• Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence (should the participant become sexually active, she must agree to use a double-barrier method of contraception). A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy.
• Women of childbearing potential who are unwilling to undergo a urine pregnancy test.
• Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the Investigator, makes the participant unsuitable from an efficacy or safety perspective.
• In the opinion of the Investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
• Currently or in last 30 days, has been in a clinical trial involving another study drug.
• Have donated blood or blood products within 30 days prior to study drug administration
• Advanced renal impairment (serum creatinine >132 µmol/L) or a risk for renal failure due to volume depletion.
• Severe known haemopoietic, renal or hepatic disease, or immunosuppressed, including any clinically significant finding from the laboratory tests results (biochemistry and hematology at screening), which, in the opinion of the Investigator, means that it would not be in the participants' best interests to participate in this study.
• History of gastric ulceration or other GI disorders that, in the opinion of the Investigator make the participant unsuitable (e.g. frequent treatment of gastroesophageal reflux disease, inflammatory bowel disease, etc).
• History of severe asthma in the opinion of the investigator.
• Has a history of drug or alcohol abuse
• Suffering from any other disease or condition which, in the opinion of the Investigator, means that it would not be in the participant's best interests to participate in this study.

• Methods of contraception that are deemed adequate have failure rates of < 1%, including: established use of oral contraceptives in conjunction with a barrier method of contraception; injected or implanted hormonal methods of contraception; placement of intrauterine device (IUD) or intrauterine system (IUS); sexual abstinence; hysterectomy; post-menopausal; sterilized; vasectomy. Suitable contraception should be used for the entire study period, from screening to follow-up. Women of childbearing age include all women that have begun puberty and had their first menstrual period until they reach menopause.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AFT Pharmaceuticals, Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Nemours Children's Health

Orlando, Florida, United States

Countries

United States

Central Contacts

Laura Boddington

Role: CONTACT

laura.boddington@aftpharm.com

+64 9 488 0232 ext 735

Facility Contacts

Lisgelia Santana-Rojas

Role: primary

4076507715

Other Identifiers

AFT-MX-16p

Identifier Type: -

Identifier Source: org_study_id